Pfizer Receives €5.3M from the Distribution of 120,000 Pneumococcal Vaccines in Catalonia

Pfizer is awarded a new contract. The U.S. pharmaceutical company has been awarded the distribution of 120,000 pneumococcal vaccines in Catalonia for $5.8 million (€5.3 million), according to a contract from the regional government.

The agreement has an execution term of one year, until December 31st, 2022. The vaccine, with the trade name Prevenar 13, is indicated for the protection of children from six weeks of life, up to five years of age. Pneumococcus is a pathogen capable of causing various infections and severe invasive processes including pneumonia, sinusitis, and peritonitis. In addition, it can also cause severe invasive processes such as meningitis, particularly in the elderly, children, and immunocompromised patients.

The Department of Health justifies this expense due to the campaign of “active immunization against invasive disease and pneumonia in people especially susceptible to suffer its complications”. The administration schedule is divided into three doses, with inoculation at two, four, and eleven months.

The regional administration does not foresee the possibility of an extension of the award, according to the contract justification. The doses will be distributed among ten localities and eleven different centers. The transport time of the doses will not exceed 48 hours, from the time the product leaves the laboratory until it reaches its destination.

Read more about Pfizer and its pneumococcal vaccine, and find the most important business headlines from around the world with our companion app, Born2Invest.

Pfizer is the only company that has a pneumococcal vaccine in Spain with an indication from six weeks of age

The vaccines will be distributed among various medical centers and warehouses in Barcelona, L’Hospitalet del Llobregat, Tarragona, Sabadell, Terrassa, Mataró, Sant Sadurní d’Anoia, Ripollet, Montornès del Vallès and Sant Fruitós de Bages.

The tender budget has been determined on the basis of the needs foreseen by the Department of Health for the year 2022, according to the estimated number of units and unit prices, so that each dose is priced at $47.3 (€42.85).

Prior to the award of this contract, the Catalan administration asked the Spanish Agency of Medicines and Health Products (Aemps) for the list of companies that have the pneumococcal conjugate vaccine in Spain with indications from six weeks of age.

The unit price for each dose is $47.3 (€42.85)

Subsequently, the Aemps issued a certificate in which it stated that there is currently only one vaccine authorized for marketing: Prevenar 13 from the Pfizer laboratory, as highlighted in the tender document.

In November, the Community of Madrid invested $27.3 million (€24.7 million) to acquire 600,000 doses of the thirteenvalent pneumococcal conjugate vaccine. These doses will be administered from the last quarter of 2021 and will end in the spring of 2022. Last year, another autonomous community, Castilla-La Mancha, awarded Pfizer the distribution of Prevenar 13 in the region for $683,192 (€618,380). In this case, the agreement consisted of 15,000 doses, at a unit price of $45.5 (€41.2).

__

(Featured image by k-e-k-u-l-é via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.